Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 2, 2005, Pages 154-159

  Hedelin, Hans ^a   Johansson, Niklas ^a   Ströberg, Peter ^a  

^a Department of Urology ^*  (Sweden)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Prostate volume; Serum prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLADDER CANCER; CORRELATION ANALYSIS; CYSTOSCOPY; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CYSTOSCOPY; ENDOSONOGRAPHY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RECTUM; SEVERITY OF ILLNESS INDEX; URINARY RETENTION; URINATION;

EID: 18244407763     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590510007685     Document Type: Article

References (14)

1. Boyle P, Napakov P. Epidemiology of benign prostatic hyperplasia: current perspectives. Eur Urol 1996;29(Suppl 1):7-11.
2. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". Br Med J 1994;308:929-30.
3. Abrams P. Evaluating lower urinary tract symptoms suggestive of benign prostatic obstruction. Scand J Urol Nephrol Suppl 1999;203:l-7.
4. Vesely S, Knutson T, Damber J-E, Diucio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003;37: 322-8.
5. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-404.
6. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163:13-20.
7. The Finnish Urological society. Recommendations for the care of benign hyperplasia of the prostate gland. Duodecim 1999;115:161-9.
8. Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997;24:339-51.
9. Hedelin H, Johansson N, Stroberg P. Uneven quality of referrals for lower urinary tract symptoms in men. Läkartidningen 2003;100:1435-7.
10. Lepor H, Machi G. Comparison of the AUA symptom index in unselected males and females between 55 and 79 years of age. Urology 1993;42:36-40.
11. Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and overactive bladder. BJU Int 2000;(Suppl 3):57-68,70-l.
12. Nickel JC. Effective office management of chronic prostatitis. Urol Clin North Am 1998;25:667-84.
13. Mehik A, Hellström P, Lukkarinen A, Sarpola A, Järvelin M-R. Epidemiology of prostatitis in Finnish men: a population based cross-sectional study. BJU Int 2000;86: 443-8.
14. Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH. The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995;75:622-30.